Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,375 | 2 | 99.4% |
| Food and Beverage | $77.90 | 4 | 0.6% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $12,375 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $41.58 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $20.00 | 1 | $0 (2018) |
| GENZYME CORPORATION | $16.32 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12,391 | 3 | AbbVie Inc. ($12,375) |
| 2022 | $19.26 | 1 | E.R. Squibb & Sons, L.L.C. ($19.26) |
| 2021 | $22.32 | 1 | E.R. Squibb & Sons, L.L.C. ($22.32) |
| 2018 | $20.00 | 1 | Merck Sharp & Dohme Corporation ($20.00) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/02/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $16.32 | General |
| 06/06/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease | ||||||
| 05/18/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $10,375.00 | Research |
| Study: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease | ||||||
| 07/12/2022 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.26 | General |
| Category: Neuroscience | ||||||
| 07/09/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Neuroscience | ||||||
| 08/31/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $20.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohns Disease | AbbVie Inc. | $12,375 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 74 | 94 | $13,494 | $9,066 |
| 2022 | 4 | 99 | 126 | $22,840 | $15,799 |
| 2021 | 4 | 151 | 180 | $31,524 | $23,533 |
| 2020 | 4 | 127 | 154 | $26,136 | $18,787 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 11 | 11 | $5,282 | $3,800 | 71.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 59 | $5,473 | $3,695 | 67.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $2,738 | $1,571 | 57.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 17 | 18 | $7,259 | $5,547 | 76.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 13 | 13 | $6,242 | $4,828 | 77.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 73 | $6,709 | $4,213 | 62.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 22 | 22 | $2,629 | $1,211 | 46.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 24 | 24 | $11,021 | $8,479 | 76.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 24 | 24 | $9,259 | $7,094 | 76.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 96 | $7,271 | $5,264 | 72.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 36 | 36 | $3,972 | $2,697 | 67.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Office | 2020 | 18 | 18 | $8,266 | $6,343 | 76.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2020 | 22 | 22 | $8,278 | $6,285 | 75.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 61 | 88 | $6,673 | $4,544 | 68.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 26 | 26 | $2,919 | $1,615 | 55.3% |
About Dr. Melvyn Acosta, M.D
Dr. Melvyn Acosta, M.D is a Gastroenterology healthcare provider based in Hato Rey, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1811993660.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melvyn Acosta, M.D has received a total of $12,453 in payments from pharmaceutical and medical device companies, with $12,391 received in 2023. These payments were reported across 6 transactions from 4 companies. The most common payment nature is "" ($12,375).
As a Medicare-enrolled provider, Acosta has provided services to 451 Medicare beneficiaries, totaling 554 services with total Medicare billing of $67,184. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Hato Rey, PR
- Active Since 06/27/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1811993660
Products in Payments
- ZEPOSIA (Drug) $41.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.